UPM Biomedicals, the forerunner in producing high quality nanofibrillar cellulose for life science and clinical applications, has signed an extensive distribution agreement for GrowInk bioinks with Brinter, a Finnish-US medtech/biotech company focusing on the development of cartilage implants using their patented 3D bioprinting technology.

The agreement grants Brinter the distribution rights of GrowInk bioinks in United States, Canada, Mexico, Finland, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Netherlands, Malta, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Australia and New Zealand.

Dr. Johana Kuncova-Kallio, Director, UPM Biomedicals, said: “We are happy to enter into distribution agreement with Brinter, a Finnish-US company with global outreach. With Brinter, we are looking forward to entering even more company laboratories and hospitals with our GrowInk bioinks. Let’s wave the “made in Finland used around the globe” flag together!”

Dr. Eva Mueller, Head of Products, Brinter, said: “This collaboration marks a significant milestone in advancing the field of 3D bioprinting and regenerative medicine together. We are excited about the impact this partnership will have on driving innovation in the life science and clinical sectors.”